[ad_1]
The price-to-book ratio of Akari Therapeutics, Plc NasdaqCM: AKTX is 1.573115. The price-to-book ratio is the share price of a company divided by the book value per share. A lower price-to-book ratio indicates that the security may be undervalued. Similarly, the price / cash flow ratio is another useful ratio for determining the value of a business. The cost-benefit ratio for Akari Therapeutics, Plc (NasdaqCM: AKTX) is. This ratio is calculated by dividing the market value of a business by the cash flow from operating activities. In addition, the price / earnings ratio is another popular way for analysts and investors to determine the profitability of a company. The price / earnings ratio for Akari Therapeutics, Plc (NasdaqCM: AKTX) is -0.964857. This ratio is calculated by dividing the current share price by earnings per share
. There is also a lot of information that is not easy to measure such as the competitive advantage, the quality of the staff and the reputation of the company. Because there are forces such as the human element that come into play when selecting stocks, prices may not always move as expected. Even after encrypting all the numbers and digging deep into a specific company, the performance of the stock might not match expectations. Investors can realize that sometimes perception can be more powerful than reality. Human emotions can change very quickly, as does the dominant sentiment of the market.
There are many tools for determining whether a business is profitable or not. One of the most popular ratios is the "Return on Assets" (ROA). This score indicates the profitability of a company in relation to its total assets. The return on assets of Akari Therapeutics, Plc (NasdaqCM: AKTX) is -0.710075. This number is calculated by dividing the net profit after tax by the total assets of the company. A company that manages its assets well will have a higher return, while a company that mishandles its assets will have a lower return.
The Piotroski F-Score is a rating system between 1 and 9 that determines the financial strength of a company. The score helps to determine if the stock of a company is valuable or not. The Piotroski F score of Akari Therapeutics, Plc (NasdaqCM: AKTX) is 1. A score of nine indicates a high value stock, while a score of one indicates a low value stock. The score is calculated based on the return on assets (ROA), the return on liquid assets (CFROA), the change in return on assets and the quality of profits. It is also calculated based on the evolution of the debt ratio or the leverage effect, the liquidity and the variation of the shares outstanding. The score is also determined by the change in the gross margin and the change in the turnover of the assets.
Investors may be interested in seeing the gross margin score on the shares of Akari Therapeutics, Plc (NasdaqCM: AKTX). The name currently has a score of 50. This score is derived from the stability of gross margin (Marx) and growth over the past eight years. The gross margin score is on a scale of 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be considered negative.
Akari Therapeutics, Plc (NasdaqCM: AKTX) has a current MF ranking of 19355. Developed by Joel Greenblatt, hedge fund manager, the goal of the formula is to locate companies of great quality that are trading at an attractive price. The formula uses ROIC and profit-return ratios to find undervalued quality stocks. In general, companies with the lowest combined rank may be the top quality choices.
In addition we can see that Akari Therapeutics, Plc (NasdaqCM: AKTX) has a shareholder return of -0.295491 and a shareholder return (Mebane Faber) of -0.29549. The first value is calculated by adding the dividend yield to the percentage of shares redeemed. The second value adds to the return on net debt reimbursed in the calculation. Shareholder return has the ability to show how much money the company is giving back to shareholders through a few different avenues. Companies can issue new shares and buy back their own shares. This can happen at the same time. Investors can also use shareholder returns to evaluate a basic rate of return.
By checking on some evaluation rankings, Akari Therapeutics, Plc (NasdaqCM: AKTX) has a Composite Value score of 78. Developed by James O 'Shaughnessy, the VC score utilizes five key ratios. # 39; evaluation. These ratios are price / earnings, cash flow, EBITDA to EV, book value and sales price. The resume is displayed in the form of a number between 1 and 100. In general, a firm with a score closer to 0 would be considered undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder return, we can see the Composite Value 2 score that is currently sitting at 83.
Volatility / PI
Volatility of stocks is a percentage that indicates whether a stock is a desirable purchase. Investors are looking at Volatility 12m to determine whether a company has a low percentage of volatility or not during a year. The Volatility 12m from Akari Therapeutics, Plc (NasdaqCM: AKTX) is 94.1914. This is calculated by taking the weekly normal log yields and the standard deviation of the price of the stock over an annualized year. The lower the number, the lower the volatility. Volatility 3m is a similar percentage determined by the daily normal daily yields and the standard deviation of the price of the stock over 3 months. The 3m Volatility of Akari Therapeutics, Plc (NasdaqCM: AKTX) is 65.9793. The 6m volatility is the same except measured over a six month period. Volatility 6m is 67.211
The Price Index is a ratio that indicates the performance of a course over a past period. The price index of Akari Therapeutics, Plc (NasdaqCM: AKTX) for the last month was 1.08421. This is calculated by taking the current stock price and dividing it by the stock price a month ago. If the ratio is greater than 1, it means that there has been an increase in prices during the month. If the ratio is less than 1, then we can determine that there has been a price decrease. Investors also look for stock prices over 12-month periods. The 12m price index for Akari Therapeutics, Plc (NasdaqCM: AKTX) is 0.45778.
Source link
